Current clinical trial studies of anti-CD22 CAR-NK cells (NCT03692767) and dual anti-CD19/CD22 CAR-NK cells (NCT03824964) are planned against relapsed and refractory B Cell lymphoma. The gene discussed is CD22; the disease is B-cell non-Hodgkin lymphoma.